Please ensure Javascript is enabled for purposes of website accessibility Horizon Biotechnology Fund - Janus Henderson Investors - Europe PA Finland
For financial professionals in Finland

Horizon Biotechnology Fund

A fund investing in innovative companies addressing high unmet medical needs or improving the standard of care in the fast-growing biotechnology sector.

ISIN
LU2441282626

NAV
EUR 18.94
As of 17/06/2025

1-Day Change
EUR -0.15 (-0.79%)
As of 17/06/2025

Morningstar Rating

As of 31/05/2025

Overview

INVESTMENT OBJECTIVE

The Biotechnology Fund aims to provide capital growth.

The Fund invests at least 80% of its net assets in equities and equity-related instruments of biotechnology and biotechnology-related companies worldwide. “Biotechnology and biotechnology-related companies” is defined as:

More

• companies that are included in the NASDAQ Biotechnology Index;
• companies that develop small molecule or biologic drugs subject to the approval of global regulatory agencies;
• companies that market products or services to aid in the research and development of small molecule or biologic drugs; or
• companies that are considered such by the Investment Manager.

In choosing investments, the Investment Manager aims to select biotechnology companies that he or she believes to be undervalued, with greater potential for clinical and/or commercial success than is currently reflected in market prices.

The Fund may invest in companies of any size, including smaller capitalisation companies.

Equity-related instruments may include depository receipts and derivative instruments (such as futures, forwards, equity swaps (also known as contract-for-differences), swaps and options and warrants).

The Fund may use derivative instruments for investment purposes (up to 10% of its net assets) and hedging purposes. The underlyings consist of a range of securities or indices that the Fund may invest in according to the Fund’s investment objective and policy,

The Investment Manager may from time to time consider hedging currency and interest rates exposure, but will not generally enter into contracts involving a speculative position in any currency or interest rate.

On an ancillary basis and for defensive purposes, the Fund may invest in:
• convertible bonds and associated derivative instruments;
• cash, money market instruments or derivative instruments that are used to provide downside market protection or dampen market volatility.

Less

The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested.
Potential investors must read the prospectus, and where relevant, the key investor information document before investing.
This website is a Marketing Communication and does not qualify as an investment recommendation.

ABOUT THIS FUND

Experienced and Specialised Investment Team: Dedicated biotechnology specialists with deep scientific backgrounds and a distinguished record of investing in biotechnology stocks. This highly specialised team is supported by the larger Janus Henderson health care team with over a century of combined health care investing experience.

Differentiated Fundamental Research: Seek to understand the science and the business to identify opportunities and mitigate the clinical and commercial risks inherent in the sector.

Disciplined Investment Process: Balanced across development stage, early commercial and profitable biotechnology companies and augmented by a differentiated Value at Risk Framework designed to mitigate the volatility associated with drug development.

Past performance does not predict future returns. 
 

RATINGS AND AWARDS

2024 Lipper Awards Winner United States
Lipper Fund Awards based on Horizon Biotechnology A2 USD shares only. Availability of this share class may be limited by law in certain jurisdictions. Performance records are detailed on the specific KID, fees and charges may vary and further information can be found in the fund’s prospectus and KID which must be reviewed before investing. Please consult your local sales representative if you have any further queries.

TOP HOLDINGS

Top holdings can be found in the factsheet of the fund.

Portfolio Management

Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Agustin Mohedas, Ph.D.

Portfolio Manager | Research Analyst

Industry since 2014.

Performance

Past performance does not predict future returns. All performance data includes both income and capital gains or losses and reflects the deduction of any ongoing charges or other fund expenses.
Cumulative & Annualised Performance (%)
As of 31/05/2025
IU2 EUR (Net) NASDAQ Biotechnology Total Return Sector Equity Biotechnology - OE
 
  Cumulative Annualised
  1MO YTD 1YR 3YR 5YR 10YR Since Inception
25/02/2022
IU2 EUR (Net) -4.94 -16.50 -13.42 14.74 - - 10.63
NASDAQ Biotechnology Total Return -3.95 -13.33 -10.60 2.07 - - 1.08
Sector Equity Biotechnology - OE -2.10 -12.56 -9.35 0.34 - - -1.80
Calendar Year Returns (%)
As of 31/03/2025
IU2 EUR (Net) NASDAQ Biotechnology Total Return Sector Equity Biotechnology - OE
YTD 2024 2023 Performance Inception
IU2 EUR (Net) -11.55 13.24 17.10 25.54
NASDAQ Biotechnology Total Return -5.39 6.07 1.05 11.46
Sector Equity Biotechnology - OE -6.38 2.20 1.69 3.72

Recommended holding period 5 Years

Example Investment: EUR 10,000

Scenarios If you exit after 1 year If you exit after 5 years
MinimumThere is no minimum guaranteed return. You could lose some or all of your investment
StressWhat you might get back after costs2,800 EUR1,780 EUR
Average return each year-72.04%-29.21%
UnfavourableWhat you might get back after costs6,670 EUR8,770 EUR
Average return each year-33.33%-2.59%
ModerateWhat you might get back after costs10,580 EUR17,640 EUR
Average return each year5.75%12.02%
FavourableWhat you might get back after costs16,870 EUR24,350 EUR
Average return each year68.74%19.48%

As of 31/03/2025
IU2 EUR (Net) NASDAQ Biotechnology Total Return Sector Equity Biotechnology - OE
Fee Information
Initial Charge 5.00%
Annual Charge 0.90%
Ongoing Charge
(As of 30/06/2023)
1.02%
Performance Fee 20% of the 'Relevant Amount'
Hurdle Rate NASDAQ Biotechnology Total Return Index

Documents

  • The value of the Funds and the income from them is not guaranteed and may fall as well as rise. You may get back less than you originally invested.
  • Past performance does not predict future returns.
  • Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.
  • Funds incur costs as a necessary part of buying and selling the underlying investments, these are otherwise known as portfolio transaction costs, and include charges such as broker commission and Stamp Duty.
  • Before investing in any of our funds you should satisfy yourself as to the suitability and the risks involved.
  • Summary of Investor rights
  • Janus Henderson Investors Europe S.A. may decide to terminate the marketing arrangements of this Collective Investment Scheme in accordance with the appropriate regulation.
  • Information on compliance with EU Sustainability related disclosures can be found here.
  • For detailed product information including the risks associated with investing please read the relevant Prospectus or Annual Report. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions.
  • The Legal Entity Identifier for this product is 213800AV3O5CVAEQM982.